Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II lebrikizumab plus topical corticosteroids for moderate to severe atopic dermatitis
NL-OMON42001Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Aug 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of lebrikizumab in atopic dermatitis (AD), sponsored by Roche. Started Aug 2015; status: active, not recruiting.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON42001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42001.